US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial following the planned first interim analysis.
The ongoing FIERCE-HN trial continues to enrol patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) and aims to recruit 410 to 500 patients.
The global, multicentre, randomised, double-blind, placebo-controlled Phase 3 clinical trial is evaluating ficlatuzumab in combination with ERBITUX (cetuximab), an anti-epidermal growth factor receptor (EGFR) antibody, as compared to placebo plus cetuximab, in patients with HPV-negative R/M HNSCC.
Ficlatuzumab is AVEO's investigational antibody that targets hepatocyte growth factor (HGF).
Hansa's imlifidase Biologics License Application accepted by FDA
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
Merck and Mayo Clinic launch AI-driven drug discovery collaboration
Palisade Bio makes Clinical Advisory Board appointment
Curasight announces presentation at TD Cowen's 46th Annual Health Care Conference in Boston
Nucleome Therapeutics names new chief scientific officer
Celltrion data show subcutaneous infliximab restores disease control after treatment interruption
Cambridge Cognition expands into India through Ivory commercialisation agreement
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
Ella immunoassay platform gains CE‑IVD approval in the EU
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer